See the DrugPatentWatch profile for lyrica

Schedule exceptions for Lyrica (pregabalin) are determined by the Drug Enforcement Administration (DEA) based on the drug's potential for abuse and medical use. According to the DEA, Lyrica is a Schedule V controlled substance, which means it has a lower potential for abuse than Schedule I, II, III, and IV drugs [1].

However, the DEA allows schedule exceptions for certain circumstances, such as for medical, scientific, or industrial purposes [1]. These exceptions are granted on a case-by-case basis and must be approved by the DEA.

Regarding Lyrica, DrugPatentWatch.com states that there are no current schedule exceptions for pregabalin in the United States [2]. This information is based on the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book [2].

It is important to note that any schedule exception for Lyrica would be subject to strict regulations and monitoring by the DEA to ensure the proper use and distribution of the drug.

In summary, while schedule exceptions for Lyrica are possible, there are currently no such exceptions for pregabalin in the United States. Healthcare professionals should always follow the DEA's guidelines and regulations when prescribing and dispensing controlled substances.

Sources:
[1] Drug Enforcement Administration. (n.d.). Controlled Substance Schedules. Retrieved from <https://www.dea.gov/drug-scheduling>
[2] DrugPatentWatch.com. (2023). Pregabalin. Retrieved from <https://www.drugpatentwatch.com/drugs/pregabalin>